Fmr Llc Sells 290,912 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) Stock

Sana Biotechnology, Inc. (NASDAQ:SANA) insider Fmr Llc sold 290,912 shares of the stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now directly owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sana Biotechnology Stock Performance

Shares of Sana Biotechnology stock opened at $3.66 on Friday. The business’s 50 day moving average price is $2.40 and its 200 day moving average price is $4.05. The company has a market cap of $817.16 million, a price-to-earnings ratio of -2.61 and a beta of 1.45. Sana Biotechnology, Inc. has a one year low of $1.52 and a one year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. On average, analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in SANA. Wilmington Savings Fund Society FSB purchased a new position in Sana Biotechnology in the third quarter worth approximately $29,000. Stifel Financial Corp purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth $43,000. EP Wealth Advisors LLC purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth $45,000. Blue Trust Inc. increased its position in shares of Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after purchasing an additional 12,154 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new stake in Sana Biotechnology in the 3rd quarter valued at about $67,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HC Wainwright raised their target price on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Wednesday. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Finally, TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.25.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.